Adaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research report issued to clients and investors on Friday. The firm set a “buy” rating on the biotechnology company’s stock.

Separately, Mizuho decreased their target price on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $2.79.

Adaptimmune Therapeutics Stock Down 37.7 %

Shares of Adaptimmune Therapeutics stock opened at $0.28 on Friday. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The business has a 50-day moving average price of $0.55 and a 200 day moving average price of $0.71. Adaptimmune Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $1.65. The firm has a market cap of $71.65 million, a P/E ratio of -1.27 and a beta of 2.52.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several hedge funds have recently made changes to their positions in the company. Invesco Ltd. boosted its position in shares of Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after buying an additional 28,526 shares during the period. Two Sigma Advisers LP raised its position in Adaptimmune Therapeutics by 492.0% during the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 58,787 shares during the period. Two Sigma Investments LP lifted its stake in Adaptimmune Therapeutics by 33.5% in the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 19,146 shares in the last quarter. Virtu Financial LLC boosted its position in Adaptimmune Therapeutics by 21.5% during the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 21,688 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in Adaptimmune Therapeutics during the 3rd quarter valued at about $95,000. Hedge funds and other institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.